News & Events :: Rigel Pharmaceuticals, Inc. (RIGL)
Dec 9, 2024 · Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
Press Releases :: Rigel Pharmaceuticals, Inc. (RIGL)
Dec 2, 2024 · Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for ...
Oct 24, 2024 · SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company …
Rigel Pharmaceuticals Completes Transfer of GAVRETO® …
This press release contains forward-looking statements relating to, among other things, the potential benefits of Rigel's acquisition of U.S. rights to GAVRETO, including opportunities in …
Rigel Announces Publication of Data on REZLIDHIA® …
Apr 4, 2024 · SOUTH SAN FRANCISCO, Calif., April 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in …
News & Events - Rigel Pharmaceuticals, Inc.
Dec 1, 2022 · SOUTH SAN FRANCISCO, Calif., Dec. 1, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the U.S. Food and Drug …
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
Feb 22, 2024 · Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings; …
Rigel Announces R289 Granted Fast Track Designation by the FDA …
Dec 2, 2024 · SOUTH SAN FRANCISCO, Calif., Dec. 2, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused …
Rigel Reports Third Quarter 2024 Financial Results and Provides ...
Nov 7, 2024 · SOUTH SAN FRANCISCO, Calif., Nov. 7, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused …
Investor Relations :: Rigel Pharmaceuticals, Inc. (RIGL)
Nov 7, 2024 · Latest News Dec 9, 2024 • 12:02pm EST Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition